Ulysses Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Ulysses Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-25,000	Closed	-$2.12M	–	67
2017 Q4	$2.12M	Buy	+25,000	New	+$2.09M	0.23%	38
2017 Q2	–	Sell	-20,000	Closed	-$1.39M	–	64
2017 Q1	$1.39M	Buy	+20,000	New	+$1.34M	0.22%	37

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Ulysses Management's XBI Position: Q1 2026 in Review

Ulysses Management held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q1 2026 at 15,000 shares worth $1.92M. The position accounts for 0.24% of the portfolio, ranked #25.

Ulysses Management first reported a position in XBI in Q2 2017 and has held it in 13 quarters since. The position peaked at $2.12M in Q3 2024. 814 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Ulysses Management held 15,000 shares of State Street SPDR S&P Biotech ETF worth $1.92M as of Q1 2026.
Ulysses Management left its State Street SPDR S&P Biotech ETF share count unchanged in Q1 2026.
State Street SPDR S&P Biotech ETF made up 0.24% of Ulysses Management's portfolio in Q1 2026, its #25 holding.
Ulysses Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2017 and has held it in 13 quarters since.
Ulysses Management's State Street SPDR S&P Biotech ETF position peaked at $2.12M in Q3 2024.
814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Ulysses Management's 13F filing for Q1 2026, filed 15 May 2026.